Bank of America Corporation reiterated their buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) in a report published on Wednesday.

Other equities analysts have also issued reports about the stock. Craig Hallum boosted their price target on shares of Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Vetr upgraded shares of Exact Sciences Corporation from a hold rating to a buy rating and set a $36.13 price target on the stock in a research report on Wednesday, May 10th. Jefferies Group LLC restated a buy rating and issued a $35.00 price target on shares of Exact Sciences Corporation in a research report on Tuesday, May 16th. Canaccord Genuity restated a buy rating and issued a $27.00 price target on shares of Exact Sciences Corporation in a research report on Monday, April 24th. Finally, Leerink Swann set a $38.00 price target on shares of Exact Sciences Corporation and gave the company a buy rating in a research report on Friday, April 28th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Exact Sciences Corporation presently has an average rating of Buy and an average price target of $40.37.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up 4.06% during midday trading on Wednesday, hitting $39.47. 1,969,011 shares of the company’s stock traded hands. The company has a 50 day moving average price of $36.19 and a 200 day moving average price of $27.48. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $42.18. The firm’s market capitalization is $4.70 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities analysts anticipate that Exact Sciences Corporation will post ($1.18) earnings per share for the current year.

WARNING: “Exact Sciences Corporation (EXAS) Rating Reiterated by Bank of America Corporation” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.watchlistnews.com/exact-sciences-corporation-exas-rating-reiterated-by-bank-of-america-corporation/1462662.html.

In related news, SVP D Scott Coward sold 1,987 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.00% of the company’s stock.

Large investors have recently bought and sold shares of the company. Sheaff Brock Investment Advisors LLC increased its position in Exact Sciences Corporation by 37.9% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 14,200 shares of the medical research company’s stock valued at $335,000 after buying an additional 3,900 shares during the period. Meadow Creek Investment Management LLC increased its position in Exact Sciences Corporation by 36.0% in the first quarter. Meadow Creek Investment Management LLC now owns 214,368 shares of the medical research company’s stock valued at $5,063,000 after buying an additional 56,700 shares during the period. Tyers Asset Management LLC increased its position in Exact Sciences Corporation by 36.0% in the first quarter. Tyers Asset Management LLC now owns 122,496 shares of the medical research company’s stock valued at $2,893,000 after buying an additional 32,400 shares during the period. Elkfork Partners LLC increased its position in Exact Sciences Corporation by 36.0% in the first quarter. Elkfork Partners LLC now owns 168,432 shares of the medical research company’s stock valued at $3,978,000 after buying an additional 44,550 shares during the period. Finally, C WorldWide Group Holding A S increased its position in Exact Sciences Corporation by 9.2% in the first quarter. C WorldWide Group Holding A S now owns 191,154 shares of the medical research company’s stock valued at $4,515,000 after buying an additional 16,154 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.